

1 **Title**

2 **Global solidarity in genomic surveillance improves early detection of**  
3 **respiratory virus threats**

4 **Authors**

5 Simon P.J. de Jong<sup>1</sup>, Brooke E. Nichols<sup>2,3,4</sup>, Aniek de Ruijter<sup>5</sup>, Edyth Parker<sup>6</sup>, Vera  
6 Mitesser<sup>6</sup>, Christian Happi<sup>6</sup>, Menno D. de Jong<sup>1</sup>, Alvin X. Han<sup>1\*</sup>, Colin A. Russell<sup>1\*</sup>

7  
8 **Affiliations**

9  
10 <sup>1</sup>Department of Medical Microbiology & Infection Prevention, Amsterdam University  
11 Medical Centers, University of Amsterdam, Amsterdam, The Netherlands

12 <sup>2</sup>Amsterdam Institute for Global Health and Development, Department of Global Health,  
13 Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The  
14 Netherlands

15 <sup>3</sup>Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland

16 <sup>4</sup>Department of Global Health, Boston University, Boston, MA, USA

17 <sup>5</sup>Law Centre for Health and Life, Faculty of Law, University of Amsterdam, Amsterdam, The  
18 Netherlands

19 <sup>6</sup>African Centre of Excellence for Genomics and Infectious Diseases, Ede, Nigeria

20  
21 \*Contributed equally

22  
23 Correspondence: [c.a.russell@amsterdamumc.nl](mailto:c.a.russell@amsterdamumc.nl)

24

## 25 **Abstract**

26 Public health decision-making for respiratory virus outbreaks relies heavily on genomic  
27 sequencing to detect new (variant) viruses. However, respiratory virus sequencing  
28 infrastructure is highly unequally distributed globally, potentially limiting the efficiency and  
29 effectiveness of surveillance efforts and raising concerns about preparedness for future threats.  
30 Using mathematical models, we demonstrate that relative to global sequencing efforts during  
31 the COVID-19 pandemic, increased global solidarity in respiratory virus genomic surveillance  
32 would vastly improve the capacity to rapidly detect novel threats, even with a substantially  
33 reduced number of viruses sequenced globally, leading to improved effectiveness and  
34 efficiency. As a result, the time between a (variant) virus' first global detection and first local  
35 case would increase in all countries, allowing for more time to design and implement global  
36 and local public health measures to mitigate the threat's potential public health impacts. Our  
37 results show that operationalizing global health solidarity is key to guiding investment in  
38 preparedness for future pandemic threats.

39

## 40 Introduction

41 Genomic surveillance of respiratory viruses is a critical component of public health  
42 preparedness and response, particularly for identifying and monitoring the spread of new  
43 viruses and their variants<sup>1-3</sup>. According to Article 5 of the International Health Regulations  
44 (IHR), Member States to the World Health Organisation (WHO) are obligated to ensure  
45 national surveillance capacity<sup>4</sup>. The COVID-19 pandemic represented the zenith of global  
46 respiratory virus sequencing output so far, with ~7 million SARS-CoV-2 genomes submitted  
47 to GISAID ([www.gisaid.org](http://www.gisaid.org)) in 2022 alone. However, this output was highly unequally  
48 distributed<sup>5</sup>: half of all publicly shared genomes originated from countries that account for  
49 only 4.4% of the global human population while half of the global population accounted for  
50 only 0.7% of publicly shared genomes (Fig. 1a, Extended Data Fig. 1). Novel viruses and  
51 their variants can potentially emerge in any country. As a result, the unequal distribution of  
52 sequencing infrastructure potentially strongly limits the global capacity to rapidly detect  
53 novel threats.

54 Early detection of (variant) viruses such as potential zoonotic reassortant influenza viruses or  
55 highly genetically divergent SARS-CoV-2 variants maximises the time available to  
56 characterise the threat posed and design and implement potential interventions and mitigation  
57 strategies<sup>1,6-8</sup>. Hence, it is paramount for minimising potential public health impacts. To  
58 guide efforts toward improved preparedness for future respiratory virus threats, it is important  
59 to understand how the global landscape of genomic surveillance capabilities impacts the  
60 ability to swiftly identify new respiratory viruses and their variants. Furthermore, planning  
61 towards enhanced preparedness requires meaningful minimum sequencing targets as well as  
62 functional upper bounds for effective and efficient detection of new (variant) viruses<sup>2,3,5,9-11</sup>.

63 We aimed to quantify how the global distribution of clinical genomic surveillance  
64 infrastructure affects the global capacity to rapidly detect and characterize the spread of a  
65 novel respiratory virus (variant). First, we used a mathematical model to determine a target  
66 minimum global sequencing capacity that balances effective performance and efficient  
67 resource use. Then, we leveraged large-scale epidemic simulations to investigate how  
68 varyingly solidaristic global distributions of genomic surveillance infrastructure affect  
69 surveillance effectiveness. We used 2022 SARS-CoV-2 sequencing output as baseline,  
70 representing an empirical pandemic scenario with unprecedentedly high but highly unequally  
71 distributed levels of virus genomic sequencing.

## 72 Results

### 73 Global variation in pandemic-period detection capacity

74 To investigate how global variation in genomic surveillance capacity impacts the speed of  
75 new variant detection, we first investigated the performance of global genomic surveillance  
76 efforts for SARS-CoV-2 in 2022, representing an empirical baseline expectation for a  
77 potential future pandemic scenario. Sequencing output in 2022 was highly unequally  
78 distributed: country-specific sequencing rates estimated from submissions to GISAID<sup>12</sup>  
79 ranged from <0.01 sequences per million people per week (S/M/wk) in some countries to  
80 >1000 S/M/wk in others (Fig. 1a). The median sequencing rate across European countries

81 amounted to 64.3 S/M/wk, compared to 0.18 S/M/wk for countries in Africa. Similarly, the  
82 median time from sample collection to deposition in GISAID (henceforth, turnaround time)  
83 ranged across countries from less than a week to hundreds of days (Fig. 1b).

84 To understand how this variation impacts potential global detection capacity, we used a  
85 global metapopulation model, validated against GLEAM<sup>13,14</sup> (Extended Data Fig. 2), to  
86 simulate hypothetical scenarios of global variant spread and subsequent detection. We  
87 performed 10,000 independent simulations for values of variant  $R_e$  ranging from 1.2 to 2. We  
88 assumed a distinct archetypal scenario of variant emergence, characterized by initial  $R_e$  and  
89 prevalence of wildtype virus, for each value of variant  $R_e$  (Extended Data Fig. 3). In each  
90 simulation, the country where the variant emerged was randomly selected based on a country  
91 population size-weighted probability. We then simulated the time to first variant detection for  
92 each metapopulation epidemic simulation, given empirical country-specific SARS-CoV-2  
93 sequencing rates and turnaround times in 2022 (Fig. 1a,b).

94 Averaged across simulated variant  $R_e$  values, the mean time to first variant detection globally  
95 was 83.0 days (95% CI 18 – 194), with substantial variability especially at lower values of  
96 variant  $R_e$  (Fig. 1c). The simulated global number of variant infections by the day of first  
97 global detection varied widely (mean 632,899 infections, 95% CI 77 – 5,917,647), spanning  
98 up to five orders of magnitude for all values of variant  $R_e$  (Fig. 1d). In many simulations, new  
99 variants were first detected outside of their continent of origin, driven especially by variants  
100 first emerging in Africa (first detected outside origin continent in 75.0% of simulations), Asia  
101 (23.5%) and South America (19.1%) (Fig. 1e). This means that the variant would have  
102 frequently spread widely within and between continents prior to initial detection (consistent  
103 with, for example, the early spread and detection of the SARS-CoV-2 Omicron BA.1  
104 variant<sup>1</sup>). The continent in which the variant first emerged strongly shaped the time to variant  
105 detection (Fig. 1f) and the number of global variant infections by the day of first detection  
106 (Fig. 1g), the latter ranging from a mean of 23,006 infections (95% CI 29 – 242,943) when  
107 emerging in Europe to 1,757,677 infections (95% CI 1028 – 13,369,527) in case of  
108 emergence in Africa across simulated values of variant  $R_e$ . Differences in time to variant  
109 detection were strongly and highly nonlinearly associated with the sequencing capacity in the  
110 country of origin of the novel virus, with low sequencing rates being associated with longer  
111 times to variant detection (Fig. 1h).

## 112 **Operationalizing global health solidarity**

113 Globally, there is a shared risk of the emergence of pandemic viruses or their variants. In  
114 contrast, the results above indicate the capacity to rapidly detect new (variant) viruses is  
115 profoundly asymmetrically distributed. In part, this imbalance reflects a deficit of global  
116 health solidarity. Solidarity as a principle specifically underlies institutionalized forms of  
117 sharing as a result of mutual dependence<sup>15,16</sup>; it gives guidance to human action in the face of  
118 interdependency related to the shared risks of communicable disease, and underlies the  
119 obligations reflected in the IHR<sup>17,18</sup>. Given that pandemic risk is globally shared, we sought  
120 to investigate how more or less solidaristic approaches to respiratory virus genomic  
121 surveillance could lead to varying effective and efficient outcomes for purpose of the global  
122 detection of novel (variant) respiratory viruses. To do so, we specifically considered national

123 respiratory virus genomic surveillance capacity. We first sought to identify a minimum  
124 sequencing capacity at the national level that could serve as a target toward improving global  
125 capacity for rapid global (variant) virus detection. Ideally, this target would ensure timely  
126 information for public health action as well as efficient use of potentially limited resources. It  
127 would also need to be realistically attainable and sustainable in pandemic and inter-pandemic  
128 periods.

129 To identify a target minimum global sequencing capacity, we explored the relationship  
130 between sequencing rate, turnaround time, and time to variant detection in any single country  
131 in more detail. Representing a scenario of emergence of a potential future pandemic  
132 respiratory virus (variant), we simulated the emergence of a variant virus in the background  
133 of circulating wildtype virus and computed the expected time to variant detection based on  
134 binomial sampling for different sequencing rates. We then derived a new mathematical model  
135 characterising the relationship between sequencing rates and time to detection of the new  
136 virus variant. For a variant virus, introduced in a population at an initial frequency  $f_0$ , where  
137 the change in variant proportion through time can be described by a logistic growth rate  $s$ , the  
138 time since variant introduction when the variant virus is expected to have been detected with  
139 confidence level  $1-q$  when sequencing  $n$  samples per unit time is equal to  
140  $(\log[(q^{-s/n}-1)/f_0]+1)/s$  (Extended Data Fig. 4). This model is applicable to all respiratory  
141 viruses that can be described by SIR dynamics<sup>19</sup>, including SARS-CoV-2, seasonal influenza  
142 virus, respiratory syncytial virus, and potential future pandemic respiratory viruses.

### 143 **Benefits of increases in sequencing rate are rapidly diminishing**

144 For all modelled scenarios of variant emergence (Extended Data Fig. 3), time to variant  
145 detection rapidly decreased as sequencing rate increased up to  $\sim 10$  S/M/wk while the benefits  
146 of increases in sequencing rate beyond 10 S/M/wk were much smaller (Fig. 2a, Extended  
147 Data Fig. 5a). In 2022, many high-income countries sequenced SARS-CoV-2 genomes at  
148 rates well in excess of 10 S/M/wk, whereas sequencing rates in many lower-and-middle-  
149 income countries were such that, in absolute terms, small increases would substantially speed  
150 up variant detection (Fig. 2a, Extended Data Fig. 5a). For example, in a country of 100  
151 million people sequencing at the median 2022 SARS-CoV-2 sequencing rate in low-income  
152 countries (0.035 S/M/wk), increasing the sequencing rate by 1 S/M/wk would reduce the time  
153 to detection of a variant with  $R_e = 1.6$  at 95% confidence by  $\sim 28$  days, given a wildtype  
154 prevalence of 0.5% and a wildtype  $R_e$  of 1.1 at time of variant emergence. In contrast, if the  
155 same country was sequencing at the 2022 median high-income country rate (58.9 S/M/wk),  
156 the reduction in time to detection resulting from the same 1 S/M/wk increase in sequencing  
157 rate would be only 3.5 hours (Fig. 2a, Extended Data Fig. 5b). The diminishing returns at  
158 rates characteristic of high-income countries are particularly prominent when looking at the  
159 relationship between sequencing rate and the expected number of variant infections by the  
160 day the variant has been detected (Fig. 2b, Extended Data Fig. 6a). Assuming a 14-day  
161 turnaround time, increasing the sequencing rate in a country sequencing at the median low-  
162 income country rate by 1 S/M/wk would reduce the expected number of variant infections by  
163 the time of detection with 95% confidence by  $\sim 4.5$  million infections for the scenario of  
164 variant emergence described above; in a country sequencing at the median high-income rate,

165 the same 1 S/M/wk increase would only reduce the expected number of variant infections by  
166 the day of first detection by ~60 infections (Fig. 2b, Extended Data Fig. 6b).

167 In addition to sequencing rate, turnaround time is an essential component of effective  
168 genomic surveillance<sup>2,5,20,21</sup>. For reducing time to variant detection, any reduction in  
169 turnaround time is functionally equivalent to a fold increase in sequencing rate (Fig. 2c).  
170 Reductions in turnaround time are especially valuable for the detection of variant viruses that  
171 are highly transmissible. For example, for the archetypal variant with  $R_e = 2$ , a three-week  
172 reduction in turnaround time is equivalent to an 89.0-fold increase in sequencing rate (Fig.  
173 2c). Hence, the benefits of increasing sequencing output should be carefully weighed against  
174 the gains from strengthening the ancillary infrastructure necessary for timely availability of  
175 sequencing results.

176 Using these results, we identified a possible target for a global minimum sequencing  
177 capacity. Given the identified relationship between sequencing rate, turnaround time, and  
178 time to detection, a sequencing capacity of 2 S/M/wk with a two-week turnaround time is a  
179 sensible potential global minimum target (Fig. 2a, vertical grey line). Its position at the elbow  
180 of the relationship between sequencing rate and time to detection (Fig. 2a) suggests that 2  
181 S/M/wk is efficient, and its rapid variant detection even when a highly transmissible variant  
182 emerges in the background of high wildtype prevalence suggests that it results in strong  
183 performance. We chose a relatively low turnaround time of fourteen days given the vital  
184 importance of turnaround time in shaping time to detection. A sequencing rate of 2 S/M/wk  
185 corresponds to 0.18% of the maximum country-specific SARS-CoV-2 sequencing rate in  
186 2022. If all countries sequencing at rates lower than 2 S/M/wk in 2022 were to attain this  
187 minimum capacity, the *de novo* generated sequencing capacity would represent 6.0% of  
188 global sequencing output in 2022. This suggests that in terms of raw sequencing capacity, the  
189 expansion necessary to effectuate the global minimum would be modest compared to  
190 empirical global sequencing output in a pandemic scenario.

### 191 **Global solidarity improves surveillance effectiveness and efficiency**

192 To model the effect of more solidaristic global genomic surveillance, we re-simulated the  
193 global (variant) virus detection process given the global metapopulation epidemic simulations  
194 in a scenario where all countries possessed a global minimum capacity of at least 2 S/M/wk  
195 with 14-day turnaround time. Ensuring this global minimum sequencing capacity globally  
196 while keeping sequencing output unchanged for countries that already satisfied the minimum  
197 requirement in 2022 (henceforth, strategy A) reduced mean time to global variant detection  
198 by 26.0 days to 57.0 days (95% CI 17 – 119) relative to the simulated 2022 baseline (red bar,  
199 Fig. 3a). The mean number of global variant infections by the day of detection decreased  
200 from 632,899 infections (95% CI 77 – 5,917,647) to 31,485 infections (95% CI 67 – 235,057)  
201 (red bar, Fig. 3b), and the probability that the variant was first detected in its origin continent  
202 increased from 71.0% to 96.4% (red cross, Fig. 3c).

203 Since reductions in time to detection resulting from increases in sequencing rate beyond ~10  
204 S/M/wk (Fig. 2b) are limited, we further hypothesized that relative to the 2022 baseline,  
205 limiting sequencing rates to 30 S/M/wk would have little detrimental effect on time to variant  
206 detection (Fig. 2a, vertical grey line). In our simulations, setting a 30 S/M/wk upper limit in



207 all countries relative to the 2022 baseline but no minimum requirement (henceforth, strategy  
208 B) left the expected time to first global variant detection (green bar, Fig. 3a) and the expected  
209 number of variant infections by the day of detection (green bar, Fig. 3b) largely unchanged:  
210 mean time to variant detection increased by only 4.6 days, from mean 83.0 days to 87.6 days  
211 (95% CI 22-202) (green bar, Fig. 3a), while global sequencing output was reduced by 67.0%.

212 To model a globally solidaristic approach to respiratory virus genomic surveillance, we  
213 combined the insights that establishing a global minimum sequencing capacity could strongly  
214 reduce time to variant detection whereas the reductions in time to detection beyond ~10  
215 S/M/wk rapidly diminish. Simulations indicated that in a hypothetical future pandemic  
216 scenario, ensuring a minimum global capacity of 2 S/M/wk, while also setting a 30 S/M/wk  
217 upper limit (henceforth, strategy C), could improve time to variant detection by weeks while  
218 still reducing sequencing output by 61.0% relative to the 2022 pandemic baseline (blue bar,  
219 Fig. 3a, Extended Data Fig. 7). This result suggests that achieving a global minimum  
220 surveillance capacity could allow for substantial improvements in the capacity for rapid  
221 global virus detection, even with substantially fewer total viruses sequenced globally. We  
222 also investigated a scenario of independent country-level expansion, where each country's  
223 sequencing output increased proportional to its existing rate. Independently doubling each  
224 country's 2022 sequencing output, (strategy D) would only reduce mean time to detection by  
225 7.2 days (brown bar, Fig. 3a, Extended Data Fig. 7), suggesting that siloed expansion of  
226 individual countries' sequencing output cannot replace a solidaristic global approach.

227 Initial detection is a necessary starting point for responses to potential novel threats.  
228 However, additional information beyond simple detection is often necessary to characterize  
229 the public health risk that a (variant) virus poses. For example, the SARS-CoV-2 Alpha  
230 variant was first detected in the UK in a sample collected on 20 September 2020, likely  
231 within days of its initial emergence<sup>22</sup>. However, it was not until December 2020 that  
232 epidemiological evidence of the variant's transmission advantage relative to pre-existing  
233 viruses began to accumulate<sup>22,23</sup>. To that end, we also investigated how a more solidaristic  
234 global distribution of sequencing output would affect the time elapsed until the variant would  
235 have been estimated to account for a substantial proportion of circulating virus, suggestive of  
236 a potential transmission advantage. In our simulations, the time until estimated variant  
237 frequencies, in at least one country, provided evidence with 95% confidence that the variant  
238 had reached 1% circulating frequency, decreased from 117.7 days (95% CI 42-252) for the  
239 2022 baseline to 103.8 days (95% CI 42-210) for strategy C (Extended Data Fig. 8a).

240 Correspondingly, the mean number of global infections by that day decreased from 2,072,633  
241 (95% CI 4,896-20,293,166) to 205,311 (95% CI 4,873-1,428,529) (Extended Data Fig. 8b).

242 In contrast, capping sequencing rates at 30 S/M/wk (strategy B) increased the mean time until  
243 the variant was established to have reached 1% circulating frequency somewhere globally by  
244 only 0.5 days relative to the 2022 baseline (Extended Data Fig. 8a). Mathematical models  
245 indicate that a sequencing capacity of 2 S/M/wk would ensure robust ascertainment of variant  
246 prevalence (Extended Data Fig. 9).

247 **Solidaristic approaches improve opportunities for mitigation**

248 To investigate how establishing a global minimum capacity could affect public health  
249 preparedness, we computed the mean lead time between first global detection and the first  
250 local case for all countries under the different strategies. As the first global detection of a  
251 (variant) virus represents a potential starting point for the design and implementation of local  
252 public health responses, this lead time provides a measure for individual countries of the time  
253 horizon for public health measures that aim to mitigate potential impacts. In all countries, the  
254 lead time would increase under more solidaristic distributions of global sequencing  
255 infrastructure (Fig. 3d), potentially allowing for more time to implement public health  
256 measures in preparation for variant outbreaks or nascent pandemics. For example, for the  
257 archetypal variant virus with  $R_e = 1.6$ , the mean time between first global detection and  
258 arrival in the United States was -8.5 days under the 2022 baseline, suggesting that on average,  
259 the variant would already be present in the United States by the time it was first detected  
260 globally. Under the solidaristic strategy C, the public health lead time in the US increased by  
261 two weeks to +6.6 days. The increases in lead time were stronger for lower values of  $R_e$ ; for  
262 example, for the archetypal variant with  $R_e = 1.3$ , the mean lead time increased from +114 to  
263 +144 days in Rwanda, +82 to +111 days in Kazakhstan, +47 to +76 days in Indonesia, and  
264 +21 to +51 days in the United Kingdom, for strategy C relative to the 2022 baseline.

## 265 Discussion

266 Our results indicate that operationalizing global health solidarity in respiratory virus genomic  
267 surveillance could strongly improve preparedness for potential future respiratory virus  
268 threats. Relative to siloed surveillance efforts, where countries' policies are strongly  
269 domestically focused, pursuing sustainable global capacity could substantially reduce the  
270 time to first global detection of variant viruses and the time until variant viruses are found to  
271 exhibit signatures of rapid spread. Initial detection and sequencing is a necessary first step in  
272 assessing and responding to the threat posed by novel viruses and underlies the design and  
273 deployment of countermeasures such as vaccines and therapeutics<sup>7,24</sup>. As such, earlier  
274 warning of potential threats could substantially improve the time horizon for global and local  
275 public health measures that aim to mitigate viral threats' potential impacts, and solidaristic  
276 approaches to global genomic surveillance could improve outbreak preparedness and  
277 response for all countries globally.

278 Our results suggest that only a small fraction of pandemic-period sequencing output, in the  
279 right places, could transform the global capacity to rapidly detect novel threats. This fact,  
280 combined with the fact that a country can only detect a virus that emerged elsewhere once it  
281 is already present locally, suggests that to improve outbreak preparedness, siloed expansion  
282 of surveillance capacity in countries that already possess strong capacity cannot replace  
283 solidaristic global investment, and that solidaristic approaches to genomic surveillance could  
284 yield greater public health benefit even to countries that already possess strong surveillance  
285 infrastructure locally. Our analyses are primarily focused on detecting novel (variant) viruses  
286 and tracking their spread. Hence, our arguments weighing the enhancement of local  
287 surveillance capacity against the development of basic global capacity do not consider  
288 ancillary benefits of high-intensity genomic surveillance in high-income settings such as  
289 characterization of local transmission dynamics. However, we stress the fundamental



290 immediate importance of basic global capacity for initial detection for all countries, such as  
291 in the context of vaccine development and deployment, where speed-ups of a few weeks  
292 could have substantial public health impacts globally<sup>25</sup>.

293 In our model we assumed representative sampling in the genomic surveillance process,  
294 including the ready availability and access to diagnostic tools, which does not always hold in  
295 reality<sup>26,27</sup>. As the departure from this assumption is especially strong in resource-constrained  
296 settings<sup>20,26</sup>, the reported reductions in time to variant detection resulting from the  
297 establishment of a global minimum sequencing capacity are likely underestimates.  
298 Furthermore, our model does not model the spatial distribution of the minimum capacity in  
299 the country. The spatial distribution of sequencing capacity and the structure of sample  
300 referral networks interplays with turnaround time to shape surveillance performance and  
301 affects the optimal country-level implementation of surveillance networks. Our model is not  
302 applicable to (variant) viruses with no or a detrimental effect on transmissibility such as those  
303 that only result in increased disease severity or reduced sensitivity of diagnostics.  
304 Importantly, our results are robust to biases in the estimates of turnaround time resulting from  
305 delays in sequence deposition in GISAID<sup>28,29</sup> (Extended Data Fig. 10a) and deviations from  
306 the assumed global mobility rates (Extended Data Fig. 10b).

307 While solidarity is a helpful principle to guide policy in the case of an interdependence of  
308 risks given a particular context, reaching health equity or health justice will require  
309 overcoming substantial challenges<sup>30-35</sup>. Even with the capacity to detect new viruses sooner,  
310 the capacity to respond is also distributed asymmetrically. Even if the proposed models help  
311 undergird global health solidarity, the benefits of more rapidly available vaccines or better-  
312 matched vaccine updates due to timelier detection will only extend to countries with access to  
313 these benefits<sup>30-32,36</sup>. Furthermore, rapidly detecting and sharing information concerning new  
314 (variant) viruses must not paradoxically disadvantage countries that do so. Open sharing of  
315 pathogen genomic data must operate within a system of fair access and benefit-sharing to  
316 achieve its intended public health purpose without exacerbating global health inequity<sup>33,36,37</sup>.  
317 Despite these challenges, in many countries there is a desire for enhanced genomic  
318 surveillance capacity to inform local public health responses<sup>21,27,29,38,39</sup>.

319 Given the relationship between turnaround time and sequencing rate, we proposed a  
320 sequencing capacity of 2 S/M/wk with 14-day turnaround time as a target. We note that given  
321 this capacity, the optimal sequencing rate and its balance with turnaround time depends on  
322 the characteristics of the pathogen, the epidemiological background in which the variant were  
323 to emerge, and the required timeliness of sequencing data for public health action; for  
324 example, when levels of wildtype respiratory virus circulation are very low, relatively fewer  
325 sequences might yield a better balance between surveillance performance and resource use.  
326 The proposed target aims to balance the resources necessary for surveillance in periods of  
327 seasonal circulation of respiratory pathogens with the capacity to rapidly detect and scale up  
328 capacity during potential pandemic scenarios. While our study is focused on respiratory  
329 viruses and their variants, leveraging the infrastructure associated with the proposed target for  
330 surveillance of non-respiratory pathogens would yield further benefits. Our results underscore  
331 the importance of turnaround time in shaping the effectiveness and public health utility of

332 surveillance efforts<sup>20,21</sup>, and particularly its balance with sequencing rate. Relieving barriers  
333 to attaining low turnaround times in resource-limited settings, such as the availability of  
334 reagents, is key to realizing the potential benefits of global surveillance capacity<sup>20,40</sup>.

335 While our modelling results provide a principled target that balances resource use and  
336 performance, the optimal design, including the balance of sequencing rate and turnaround  
337 time, will likely differ from country to country, depending on local constraints and priorities.  
338 Our study provides quantitative evidence of how solidaristic approaches provide a rational  
339 basis for improving global surveillance performance, but implementation requires addressing  
340 challenges related to infrastructure, personnel, and funding that currently form barriers to the  
341 implementation of genomic capacity in under-resourced settings<sup>29,40-42</sup>. To achieve the long-  
342 term advancement of global genomics capacity in these settings, coherent capacity-building is  
343 necessary, and that requires sustainable, diversified financing which minimizes dependency  
344 on single funding source while aligning well with national needs<sup>40</sup>.


345 The COVID-19 led to an unprecedented expansion of sequencing capacity globally. Some of  
346 the most consequential gains were made in resource-limited settings<sup>20,21</sup>, and it essential that  
347 such gains are maintained and where necessary expanded to maximize preparedness for  
348 future threats. Our results suggest that a global minimum respiratory virus sequencing  
349 capacity offers a path toward improved responses to respiratory virus threats, even for  
350 countries with existing strong national surveillance capacities. For these countries, supporting  
351 a global minimum sequencing capacity could yield benefits in preparation for and during  
352 potential future outbreak scenarios that are not attainable through siloed focuses on local  
353 capacity. Our study shows how a global outlook on pandemic preparedness is essential to  
354 improve both global and local public health. To improve outbreak preparedness, there is no  
355 substitute for global solidarity; it offers a path toward better responses to respiratory virus  
356 threats that would be mutually beneficial to all WHO Member States.

357

358 **Figures**

359

360




361

362 **Figure 1. The global time to variant detection based on the SARS-CoV-2 genomic**  
 363 **sequencing landscape in 2022.**

364 **(A)** Distribution of non-zero country-specific weekly sequencing rates per million people by  
 365 continent estimated from GISAID metadata ( $N = 199$ ) (AF: Africa, EU: Europe, OC:  
 366 Oceania, AS: Asia, NA: North America, SA: South America). **(B)** Distribution of median  
 367 country-specific time from sample collection to sequence deposition in GISAID, i.e.  
 368 turnaround time ( $N = 199$ ). **(C)** The distribution of days to variant detection for different  
 369 values of variant  $R_e$  in global metapopulation model simulations, each with a distinct scenario  
 370 of variant emergence ( $N = 10,000$  for each variant  $R_e$ ). Vertical lines correspond to the  
 371 median and 95% CI. **(D)** The simulated distribution of the number of global variant infections  
 372 by the day of first variant detection. **(E)** The simulated probability that the variant is first  
 373 detected in its origin continent, by origin continent. **(F)** The simulated time to variant  
 374 detection by variant origin continent. Thin and thick lines correspond to 95% and 50% CIs,  
 375 respectively. Points correspond to means. **(G)** The simulated number of global variant  
 376 infections by the day of detection by variant origin continent, analogous to **F**. **(H)** The  
 377 relationship between a country's sequencing rate and the mean time to first global detection  
 378 of a variant emerging in that country in metapopulation simulations ( $N = 160$  for each variant  
 379  $R_e$ ). Lines correspond to LOESS fits by variant  $R_e$ .

380




381

382 **Figure 2. The dependence of time to variant detection on sequencing rate and**  
383 **turnaround time for a single country.**

384 **(A)** Relationship between sequencing rate and the number of days until the variant will have  
385 been detected with 95% confidence. The small black tick marks on the x-axes in this plot and  
386 in B show country-specific SARS-CoV-2 sequencing rates for 2022. Vertical dotted lines  
387 correspond to the median SARS-CoV-2 sequencing rates for high-income (HIC) and low-  
388 income (LIC) countries in 2022. In all panels, lines are coloured by values of variant  $R_e$ , with  
389 a distinct scenario of variant emergence for each value of variant  $R_e$ ; sequencing turnaround  
390 time was assumed to be 14 days. **(B)** Relationship between sequencing rate and the expected  
391 number of variant infections by the day the variant will have been detected with 95%  
392 confidence. **(C)** Relationship between a reduction in turnaround time (in days) and the fold  
393 increase in sequencing rate that would be required to effect the same reduction in time to  
394 detection if turnaround time was kept constant.

395



396

397 **Figure 3. The time to first global detection of a new variant under varying global**  
 398 **distributions of global respiratory virus genomic surveillance infrastructure.**

399 (A) Comparison of time to variant detection for different global strategies for the global  
 400 distribution of genomic surveillance infrastructure. Each value of variant  $R_e$  corresponds to a  
 401 distinct scenario of variant emergence ( $N = 10,000$  for each). Thin and thick lines correspond  
 402 to 95% and 50% CIs, respectively. Points correspond to means. (B) The cumulative number  
 403 of global variant infections by the day of variant detection by strategy, analogous to A. (C)  
 404 The probability that the variant is first detected in its origin continent, by strategy. (D)  
 405 Comparison of the mean time between the first detection of the variant globally, and the first  
 406 local within-country infection, by strategy, for individual countries, averaged across values of  
 407 variant  $R_e$  ( $N = 195$  for each strategy). Each point corresponds to a country, coloured by  
 408 continent (AF: Africa, EU: Europe, OC: Oceania, AS: Asia, NA: North America, SA: South  
 409 America). Boxplots show the median, first and third quartiles, and minimum and maximum  
 410 values.

411

412

## 413 **Methods**

414

### 415 *Operationalizing global health solidarity*

416

417 Genomic surveillance capacity has become a core component of preparedness and response to  
418 global disease outbreaks. In accordance with Article 5 and annex 1 of the International Health  
419 Regulations (IHR), Member States of the World Health Organization (WHO) must ensure  
420 national surveillance capacity. The WHO can assist Member States to develop, strengthen and  
421 maintain surveillance capacities as needed (Article 5(4) IHR)<sup>4</sup>. Underlying this obligation is  
422 solidarity; a principle that gives guidance to human action in the face of interdependency  
423 because of the shared risks of communicable disease<sup>17,18</sup>.

424

425 Solidarity connotes a sense of commitment to help similar others in need<sup>43</sup>. More specifically  
426 solidarity – quite apart from charity or other forms of ‘helping out’ and sharing – as a principle  
427 underlies institutionalized forms of sharing as a result of mutual dependence<sup>15,16</sup>. Solidarity is  
428 relational, meaning that its institutional scope is determined by societal bounds of whom we  
429 feel solidary towards<sup>44,45</sup>. In the field of health this plays out in national schemes of health  
430 insurance, redistribution, planning and rationing to ensure access to medicines and services<sup>46,47</sup>.

431

432 The relational aspect of solidarity has made it difficult globally to determine what exactly is  
433 owed in interstate and global health interactions. In this regard it has been argued that in global  
434 health, solidarity needs to be based on ‘similarity in a *specific context*’<sup>43</sup>. In line with this  
435 presupposition, we operationalize global health solidarity here specifically considering national  
436 capacity for genomic sequencing, by modelling for the most effective and efficient global  
437 distribution to the extent that we globally face the shared risk of unforeseeable pandemic  
438 respiratory virus occurrence. Operationalizing global health solidarity through modelling the  
439 global distribution of genomic sequencing capacity in this regard can guide WHO efforts to the  
440 implementation of Article 5 IHR, and to rationally invest in genomic sequencing capacity  
441 where needed to safeguard global pandemic preparedness as risk-sharing among WHO’s  
442 Member States.

443

### 444 *Sequence metadata analysis*

445

446 We downloaded metadata corresponding to all SARS-CoV-2 genomes in the GISAID<sup>12</sup>  
447 database with collection date from January 1<sup>st</sup> to December 31<sup>st</sup> 2022 and submission date  
448 before July 1<sup>st</sup> 2023 ( $n = 6,914,601$ ). For each country with at least one sequence in the  
449 dataset, we computed the weekly sequencing rate by dividing the number of viruses sampled  
450 in that country by 52 and the country’s population size in millions, yielding a sequencing rate  
451 in units of sequences per million people per week (S/M/wk). Population sizes for July 1<sup>st</sup>  
452 2022 were extracted from the United Nations World Population Prospects 2022  
453 (<https://population.un.org/wpp/Download/Standard/MostUsed/>). For each sequence, we  
454 computed the turnaround time from the number of days between the sample collection and  
455 submission day in GISAID. We extracted countries’ *per capita* gross domestic product  
456 (GDP) for 2022, or the most recent year before 2022 if data for 2022 was unavailable, from



457 the World Bank (<https://data.worldbank.org/indicator/NY.GDP.PCAP.CD> (last updated  
458 2023/10/26)). We extracted income classifications for each country for fiscal year 2024 from  
459 the World Bank ([https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-  
460 bank-country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)).

461

#### 462 *Variant epidemic simulations*

463

464 In all analyses, we assumed that a variant virus emerges in the context of circulating wildtype  
465 virus. In our simulations, both variant and wildtype epidemiological dynamics are described  
466 by a susceptible-infected-recovered (SIR) compartmental model with infectious period  $1/\gamma$   
467 equal to 5 days for both viruses, with no interactions between genotypes. We simulated  
468 variant epidemics under a range of values of variant  $R_e$  at time of introduction (variant  $R_e =$   
469 1.2, 1.3, 1.6, and 2). In the main text, we assumed a different scenario of variant emergence  
470 for each value of variant  $R_e$ , characterized by a wildtype (wt)  $R_e$  at time of variant  
471 introduction and a wildtype prevalence at time of variant introduction (variant  $R_e = 1.2$ : wt  $R_e =$   
472 1, wt prevalence = 0.1%; variant  $R_e = 1.3$ : wt  $R_e = 1.05$ , wt prevalence = 0.2%; variant  $R_e =$   
473 1.6: wt  $R_e = 1.1$ , wt prevalence = 0.5%; variant  $R_e = 2$ : wt  $R_e = 1$ , wt prevalence = 2%). These  
474 scenarios were chosen such that circulation dynamics of wildtype and variant were  
475 comparable (e.g. the emergence of a highly transmissible variant in the background of high  
476 wildtype prevalence). In the Extended Data Figures, we show the same analyses for all  
477 combinations of variant  $R_e$  and scenario of variant emergence (e.g. a variant with  $R_e = 2$  with  
478 wildtype dynamics corresponding to the scenario for variant  $R_e = 1.2$  (wt  $R_e = 1$ , wt  
479 prevalence = 0.1%)). Epidemic dynamics for each scenario in the main text are shown in  
480 Extended Data Fig. 3. While we report results based on variant  $R_e$ , we note that results are  
481 primarily dependent on the logistic growth rate of the variant proportion (see section  
482 ‘*Mathematical model*’ below). In this context, the scenario of variant  $R_e = 2$  with wt  $R_e = 1$  is,  
483 for example, functionally equivalent to a scenario with variant  $R_e = 2.5$  and wt  $R_e = 1.5$ .  
484 Similarly, the first scenario of variant  $R_e = 1.2$  and wt  $R_e = 1$  is functionally equivalent to a  
485 scenario of variant  $R_e = 1.6$  and wt  $R_e = 1.3$ , approximating a scenario of emergence of a  
486 A/H1N1pdm09 pandemic-like virus early in a seasonal influenza virus epidemic.

487

#### 488 *Metapopulation model*

489

490 We used a metapopulation model that couples local SIR dynamics within each index country  
491 with global migration to simulate the global spread of a variant. Given a rate of movement  
492  $w_{nm}$  from population  $m$  to  $n$ , the expected number of variant-infected ( $I_n$ ) and variant-  
493 susceptible ( $S_n$ ) people in population  $n$  with population size  $N_n$  for a variant with  
494 transmission rate  $\beta$  and recovery rate  $\gamma$ , is described by

495

$$496 \quad \partial_t I_n = \frac{\beta S_n I_n}{N_n} - \gamma I_n + \sum_{m \neq n} (w_{nm} I_m - w_{mn} I_n)$$

$$497 \quad \partial_t S_n = \frac{-\beta S_n I_n}{N_n} + \sum_{m \neq n} (w_{nm} S_m - w_{mn} S_n)$$

498

499 This model is the basis of the model used by Brockmann et al.<sup>48</sup> to fit empirical arrival times  
500 for multiple respiratory viruses to global air transportation data. We used the estimated  
501 pairwise number of trips between all countries from the Global Transnational Mobility  
502 (GTM)<sup>49</sup> to inform  $w_{nm}$ . This dataset combines a tourism dataset from the World Tourism  
503 Organization and an origin-final destination dataset corresponding to global air travel data.  
504 Previous work has validated the GTM against the world airline network<sup>50</sup>, which Brockmann  
505 et al.<sup>48</sup> showed to strongly reproduce observed dynamics of global pathogen spread.  
506 Specifically, for any two countries  $n$  and  $m$  we computed  $w_{nm}$  by dividing the number of trips  
507 from country  $m$  to  $n$  in the year 2016 by the population size of country  $m$  and by 365. For  
508 each value of variant  $R_e$ , we performed 10,000 independent simulations of the  
509 metapopulation model, assuming that the probability a variant virus would emerge in a  
510 particular country is proportional to the country's relative population size (simulations  
511 initialized in Africa:  $n = 1793$ ; Asia:  $n = 5946$ , Europe:  $n = 934$ ; North America:  $n = 739$ ;  
512 Oceania:  $n = 54$ ; South America:  $n = 534$ ). We integrated the model forward in time at a daily  
513 timescale using a tau-leap algorithm, which also furnishes the epidemic dynamics and global  
514 spread with stochasticity. Each simulation was initialized with an infected population of 10  
515 individuals.

516

517 We validated the metapopulation model by comparing arrival times against those that were  
518 independently estimated using GLEAM<sup>14</sup>, a separate metapopulation model that incorporates  
519 commuting but which relies on different underlying data. Given an epidemic origin location,  
520 we simulated 10 epidemic instances using the metapopulation model, each initialized with 10  
521 infected individuals, and we simulated 10 instances using GLEAM, where we implemented  
522 the same SIR model. In the GLEAM simulations, we assumed 100% of airline traffic, no  
523 seasonality, and a gravity commuting model with 8 hours spent at the commuting  
524 destinations. For each country, we computed the first day on which median cumulative  
525 incidence across simulations exceeded 0.01 per 1000 individuals for both model  
526 implementations. We performed these simulations for ten countries (Cameroon, Ecuador,  
527 France, Jamaica, Malaysia, Mali, Nepal, Nicaragua, Oman, Uzbekistan) with the GLEAM  
528 model initialized in each country's capital city. For all ten origin locations we find a strong  
529 concordance between arrival times ( $r = 0.89$  overall) estimated using the metapopulation  
530 model and GLEAM (Extended Data Fig. 2). This provides support for the use of the  
531 metapopulation model.

532

### 533 *Global genomic surveillance simulations*

534

535 We performed the genomic surveillance simulations using empirical turnaround times and  
536 sampling rates for each country, using data for 2022. For each sequence in GISAID, we  
537 computed the time  $T$  between the sample's collection date and submission date. For each  
538 country  $c$ , the turnaround-time specific sequencing rate in unit of sequences per day  $n_{x,c}$ , for  
539 each value of turnaround time  $x$  in days, was equal to the country's total sequencing rate in  
540 sequences per day multiplied by the proportion of sequences from that country with  $T = x$ .

541

542 For each country in each simulation, starting from the first day on which the number of new  
543 variant infections exceeded 10 onwards, we deterministically simulated the wildtype  
544 epidemic dynamics. For each value of variant  $R_e$ , we assumed a scenario of variant  
545 emergence (characterized by a wildtype prevalence and wildtype  $R_e$ ) as described above in  
546 the main text. In the Extended Data Figures, we show the same analyses for all combinations  
547 of variant  $R_e$  and scenario of variant emergence. Until the first day on which the number of  
548 variant infections exceeded 10, wildtype incidence was assumed to be equal to wildtype  
549 incidence on the first day of the simulated wildtype epidemic, to account for the stochasticity  
550 observed when the number of infections was small and the potential for stochastic variant  
551 extinction.

552  
553 Using the simulated variant and wildtype incidence on each day, we computed the variant  
554 proportion through time  $f(t)$ . For each country  $c$ , on each day  $t$ , we used the simulated  
555 country-specific variant proportion  $f_c(t)$  to simulate genomic surveillance: For each value of  
556 turnaround time  $x$ , we assumed that total sample count  $\tilde{n}_{x,c} \sim \text{Poisson}(n_{x,c})$  and simulated the  
557 total number of variant samples  $V_c(t) = \sum_{x=0}^t v_{x,c}$ , with  $v_{x,c} \sim \text{Binomial}(\tilde{n}_{x,c}, f_c(t-x))$ . In each  
558 of 10,000 replicate simulations, and for each strategy for the global distribution of  
559 surveillance infrastructure (see next section), we computed the detection day as the first day  $t$   
560 on which  $V_c(t)$  was at least one in at least one country  $c$ . We defined the detection country as  
561 the first country for which this held.

562  
563 To investigate the time until the variant could be said to account for a substantial proportion  
564 of circulating virus in at least one country, we used the simulated weekly sequence counts to  
565 compute, for each country, if there was any week in the past in which the variant accounted  
566 for at least a proportion  $\pi$  of all samples collected that week with 95% confidence given a  
567 one-tailed binomial test for proportions. We performed this analysis on a weekly basis for  
568 each country, and the day on which the  $p$ -value for this binomial test declined below 0.05 in  
569 at least country, for any week in the past, was defined as the day the variant was established  
570 to account for a substantial proportion of circulating virus in at least one country globally. We  
571 chose  $\pi$  to be 1% for all countries with a population of 100 million individuals or fewer. We  
572 ensured a more flexible threshold for countries with a population larger than 100 million. For  
573 these countries, the threshold decreased proportionally as the population size increased, e.g.  
574 using a threshold of 0.5% for a population of 200 million individuals and a threshold of 0.1%  
575 in a population of 1 billion individuals.

576  
577 *Global surveillance strategies*

578  
579 We investigated five strategies for the global distribution of sequencing infrastructure:

580  
581 Strategy 2022: the 2022 baseline. For each country, turnaround time-specific sequencing  
582 rates were extracted from GISAID metadata.

583

584 Strategy A: the 2022 baseline + a global minimum sequencing capacity of 2 S/M/wk with 14-  
585 day turnaround time in each country. If a country already satisfied this requirement (i.e., the  
586 sum of turnaround time-specific sequencing rates with turnaround time  $\leq 14$  days was equal to  
587 or greater than 2 S/M/wk), its sequencing rates were unchanged relative to the 2022 baseline.  
588 If a country satisfied the sequencing rate across all values of turnaround time, but not within  
589 the required two-week turnaround time, the deficit in S/M/wk in the sum of turnaround time-  
590 specific sequencing rates with turnaround time  $\leq 14$  days was uniformly removed from the  
591 sequencing rates exceeding 14 days and added to the sequencing rate corresponding to a  
592 turnaround time of 14 days. Hence, in this scenario, total sequencing output remained  
593 unchanged, and the minimum sequencing capacity was attained by reducing turnaround time.  
594 If a country did not satisfy the minimum sequencing rate at all, all sequencing output  
595 corresponding to a sequencing rate  $> 14$  days was set to a turnaround time of 14 days. The  
596 remaining deficit in S/M/wk in the sum of turnaround time-specific sequencing rates with  
597 turnaround time  $\leq 14$  days was added to the sequencing rate corresponding to a turnaround  
598 time of 14 days.

599

600 Strategy B: Equivalent to the 2022 baseline, but individual countries' sequencing output  
601 capped at 30 S/M/wk. Countries that sequenced at rates exceeding 30 S/M/wk had their  
602 sequencing output capped by dividing sequencing rate uniformly across all values of  
603 turnaround time such that total output across all values of turnaround time was equal to 30  
604 S/M/wk.

605

606 Strategy C: A combination of strategies A and B. In countries that, after capping according to  
607 strategy B, did not satisfy the minimum sequencing rate of 2 S/M/wk with 14-day turnaround  
608 time, this minimum was ensured analogous to Strategy A.

609

610 Strategy D: The 2022 baseline, doubled. In each country, the sequencing rate in 2022 was  
611 doubled across all values of turnaround time. Hence, the absolute increase in sequencing  
612 output was greater in countries that had a higher baseline sequencing rate.

613

614 *Mathematical model*

615

616 For the single-country analyses presented in Figure 2, we assumed a population of 100  
617 million and turnaround time of two weeks. We deterministically simulated variant and  
618 wildtype epidemics, starting with one variant-infected individual, and computed the variant  
619 proportion  $f(t)$  through time. For each sequencing rate and given  $f(t)$ , we computed the  
620 expected day of detection with 95% confidence as the day on which the probability that zero  
621 wildtype sequences would have been binomially sampled up to and including that day  
622 declined below 0.05. On each day, the total number of samples to sequence was assumed to  
623 be a Poisson-valued random variable with rate given by the sequencing rate. For each  
624 sequencing rate, the day of detection was computed as the median across 100 replicates. To  
625 compute the equivalent fold increase in sequencing rate for each reduction in turnaround  
626 time, we computed the slope of a linear model that relates the logarithm of the sequencing  
627 rate to the simulated day of detection for  $1 < n < 100$  S/M/wk. In Extended Data Fig. 5 and 6

628 we show the analyses of time to detection for all combinations of variant  $R_e$  and scenario of  
629 variant emergence (e.g. a variant with  $R_e = 2$  with wildtype dynamics corresponding to the  
630 scenario for variant  $R_e = 1.2$  (wt  $R_e = 1$ , wt prevalence = 0.1%).

631  
632 To mathematically model time to variant detection, we assumed that the variant frequency  
633 follows a logistic growth function, where the proportion  $f(t)$  of all new infections at time  $t$   
634 that is attributable to the variant follows:

$$635 \quad f(t) = \frac{1}{1 + \frac{1-f_0}{f_0} e^{-st}}$$

636 Here,  $s$  is the logistic growth rate that defines the speed at which the variant displaces the  
637 wildtype and  $f_0$  represents the initial variant frequency. The dynamics of logistic growth of  
638 variant proportion characterized the sequential replacement of variants during the COVID-19  
639 pandemic. Assuming no interactions between genotypes, the value of  $s$  is equal to the  
640 difference of variant and wildtype exponential growth rates<sup>23</sup>. In reality,  $s$  is governed by  
641 factors such as pre-existing immunity in the population and differences in epidemiological  
642 characteristics of variant and wildtype such as their generation interval. Nevertheless, the  
643 derived relationship relies solely on the value of  $s$ , and hence is agnostic to the precise  
644 epidemiological characteristics of wildtype and variant. Given these dynamics, we derived a  
645 relationship between the number of viruses to sequence per unit time  $n$  and the expected time  
646 until the variant is detected. Beginning with the binomial probability that variant is detected  
647 at or before time step  $\tau$ :

$$648 \quad P(t \leq \tau) = 1 - \prod_{t=0}^{\tau} [1 - f(t)]^n$$

649 we derived an expression for  $\tau$ :

$$650 \quad \prod_{t=0}^{\tau} [1 - f(t)]^n = 1 - P(t \leq \tau)$$
$$651 \quad n = \frac{\ln[1 - P(t \leq \tau)]}{\ln\{\prod_{t=0}^{\tau} [1 - f(t)]\}}$$

652 Using the Volterra product integral:

$$653 \quad \prod_a^b [1 + f(x)dx] = \exp\left(\int_a^b f(x) dx\right)$$
$$654 \quad n = \frac{\ln[1 - P(t \leq \tau)]}{\ln[\exp(\int_0^{\tau} -f(t) dt)]} = \frac{\ln[1 - P(t \leq \tau)]}{-\int_0^{\tau} f(t) dt}$$

655 Integrating  $f(t)$ :

$$656 \quad F(t) = \int f(t) dt$$
$$657 \quad = \int \frac{1}{1 + \frac{1-f_0}{f_0} e^{-st}} dt$$

$$\begin{aligned}
 &= \int \frac{e^{st}}{e^{st} + \frac{1-f_0}{f_0}} dt \\
 &= \frac{1}{s} \int \frac{1}{e^{st} + \frac{1-f_0}{f_0}} s e^{st} dt \\
 &= \frac{1}{s} \ln \left| e^{st} + \frac{1-f_0}{f_0} \right| + C \\
 &= \frac{1}{s} \ln \left| \frac{f_0(e^{st} - 1) + 1}{f_0} \right| + C \\
 &= \frac{1}{s} \ln |f_0(e^{st} - 1) + 1| - \frac{1}{s} \ln \left| \frac{1}{f_0} \right| + C \\
 &= \frac{1}{s} \ln(f_0(e^{st} - 1) + 1)
 \end{aligned}$$

We can then rewrite:

$$\begin{aligned}
 n &= \frac{\ln[1 - P(t \leq \tau)]}{-F(\tau)} \\
 &= \frac{s \cdot \ln[1 - P(t \leq \tau)]}{-\ln(f_0(e^{s\tau} - 1) + 1)} \\
 \frac{n}{s} &= \frac{\ln[1 - P(t \leq \tau)]}{-\ln(f_0(e^{s\tau} - 1) + 1)}
 \end{aligned}$$

Let  $q = 1 - P(t \leq \tau)$  which is the probability that the variant will *not* be detected before or during time step  $\tau$ .

$$\begin{aligned}
 \ln(f_0(e^{s\tau} - 1) + 1) &= -\frac{s \ln q}{n} \\
 f_0(e^{s\tau} - 1) + 1 &= q^{-s/n} \\
 e^{s\tau} &= \frac{q^{-s/n} - 1}{f_0} + 1 \\
 \tau &= \frac{\ln \frac{q^{-s/n} - 1}{f_0} + 1}{s} \text{ [Eq. 1]}
 \end{aligned}$$

This equation yields, given  $s$ ,  $n$ ,  $f_0$ , and  $q$ , the day  $\tau$  on which the variant will have been detected at least once with confidence level  $1 - q$ . This equation is valid when the timescales of detection are smaller than the timescales at which the logistic growth dynamics do not hold. For example, in extreme scenarios of a very high wildtype  $R_e$ , a small variant transmission advantage and a low sequencing rate, the timescale of variant detection is beyond that of depletion of the susceptible population and the assumptions of the equation are not satisfied. We compared the predicted time to detection at 95% confidence for sequencing rates  $n$  ranging from 0.1 to 1000 S/M/wk as computed using epidemic simulations (Fig. 2a in main text) to predicted time to detection using only Eq. 1. In computing time to detection



687 using the equation, we used the empirical value of  $f_0$  from the epidemic simulations as input,  
688 with  $q = 0.05$ . We used the theoretical value of  $s$ , computed as  $(\text{variant } R_e - \text{wildtype } R_e) / 5$ .  
689 We performed this simulation for all four scenarios of variant emergence (each corresponding  
690 to a different initial wildtype  $R_e$  and wildtype prevalence) and all four values of variant  $R_e$ . As  
691 seen in Extended Data Fig. 4, there was high correspondence between the time to detection  
692 from the explicit epidemic simulations and Eq. 1 when the variant  $R_e$  was high and/or  
693 wildtype prevalence was low. In contrast, when variant  $R_e$  was low and wildtype prevalence  
694 was high, susceptible depletion would occur before the timescale at which the variant would  
695 be detected, and the time to detection as predicted using the equation would deviate from the  
696 simulated time to detection. We note that, for combinations of initial variant proportion and  
697 variant proportion logistic growth rate not explicitly discussed in this study, the mathematical  
698 model can be used to compute the expected time to variant detection.

699

#### 700 *Variant prevalence estimation*

701

702 In addition to variant detection, we investigated the relationship between sequencing rates  
703 and the accuracy with which the spread dynamics of the variant can be tracked following its  
704 detection. Specifically, we investigated the accuracy with which the weekly proportion of  
705 new infections that is attributable to the variant can be estimated, and how this accuracy  
706 depends on sequencing rate. Mathematically, assuming a small, finite population  $N$  was  
707 infected at prevalence  $p$  and samples were collected from fraction  $s$  of infected individuals  
708 during each week, the potential (finite) number of samples that could be sampled from for  
709 sequencing is  $N\rho s$ .

710

711 Suppose the true circulating proportion is  $p$  and  $n$  (i.e.  $n < N\rho s$ ) number of samples were  
712 sequenced, the number of variant sequences ( $X$ ) follows a hypergeometric distribution with  
713 mean and variance:

714

$$E(X) = np$$

715

$$Var(X) = np(1-p) \left( \frac{N\rho s - n}{N\rho s - 1} \right)$$

716 The variance of the variant proportion  $\hat{p}$  ( $= X/n$ ) showing up in the sequences is:

717

$$Var(\hat{p}) = \frac{p(1-p)}{n} \left( \frac{N\rho s - n}{N\rho s - 1} \right)$$

718 By Central Limit Theorem,  $\frac{\hat{p}-p}{\sqrt{\frac{p(1-p)}{n} \left( \frac{N\rho s - n}{N\rho s - 1} \right)}}$  follows an approximate Normal distribution.

719 As such, at 95% ( $\alpha = 5\%$ ) confidence, the error ( $\epsilon$ ) around the true variant proportion is:

720

$$\epsilon = Z_{\alpha/2} \sqrt{\frac{p(1-p)}{n} \left( \frac{N\rho s - n}{N\rho s - 1} \right)}$$

721 For sequencing rate of  $r$  sequences per million persons per week (hence  $n = \frac{rN}{c}$  where  $c =$   
722  $10^6$ ):

723 
$$\epsilon = Z_{\alpha/2} \sqrt{\frac{p(1-p)}{r} \left( \frac{c\rho s - r}{N\rho s - 1} \right)}$$

724 If  $N\rho s$  is sufficiently large (i.e.  $N\rho s \gg n = \frac{rN}{c} \rightarrow c\rho s \gg r$ ),

725 
$$\epsilon \rightarrow Z_{\alpha/2} \sqrt{\frac{p(1-p)}{r} \left( \frac{c}{N} \right)}$$

726 In Extended Data Fig. 9, we visualized the relationship between sequencing rate and the error  
727 in the estimated variant proportion, for different population sizes, true variant proportions,  
728 and values of  $\alpha$ .

729  
730 *Sensitivity analyses*

731  
732 In our analyses, we defined a sequence's turnaround time as the time between the sequence's  
733 collection date and its submission date on GISAID. This represents the most accurate  
734 measure of turnaround time available and has been used in previous analyses of global  
735 sequencing output<sup>5</sup>. Nevertheless, a potential issue with this definition of turnaround time is a  
736 lag between acquiring the sequence and its submission to GISAID, which is not reflected in  
737 these estimates<sup>28</sup>; in some cases, sequence analysis might have been performed but the  
738 sequence would only later be deposited in GISAID. To establish the sensitivity of our global  
739 simulation results to such delays in upload to GISAID, we re-simulated our global  
740 metapopulation genomic surveillance simulations, where we assumed that the day the  
741 sequence was acquired was somewhere between the sample's collection date and date of  
742 submission to GISAID. Specifically, for each sequence, we computed the modified  
743 turnaround time as  $\phi(t_{\text{submission}} - t_{\text{collection}})$ , for  $0 < \phi < 1$ . We re-simulated the genomic  
744 surveillance simulation results as presented in Figure 3 for  $\phi = 0.25, 0.5$ . Varying  $\phi$  modifies  
745 the (country-specific) turnaround time-specific sequencing rates used in the global genomic  
746 surveillance system. Results for different values of  $\phi$  are presented in Extended Data Fig.  
747 10a. For all values of  $\phi$  tested, we find that the conclusion holds that more solidaristic  
748 strategies for the global distribution of respiratory virus surveillance infrastructure (strategies  
749 A and C) offer strongly reduced time to variant detection. Hence, our results are robust to  
750 biases resulting from deviations from the assumption that the submission date represents the  
751 date on which the sample is available. Importantly, the observed consistency between a  
752 country's sequencing rate and its median turnaround time (Spearman's  $\rho = -0.60$ ,  $P = 5.1 \times$   
753  $10^{-21}$ ) suggests that a country's distribution of turnaround times as computed from GISAID  
754 yields a representative picture of a country's true capacity to rapidly sequence a virus after  
755 sample collection.

756  
757 In our model, we estimated the mobility rate  $w_{nm}$  for countries  $m$  and  $n$  by dividing the  
758 number of trips from  $m$  to  $n$  in 2016 in the GTM by the population in  $m$ . This assumes that all  
759 members of the population participate in disease-relevant spread. In reality, this will not be  
760 the case. However, for the results of our study, these differences are likely to be of little  
761 consequence. Specifically, a lower effective mobility rate would further increase the

762 reduction in time to detection that would result from the establishment of minimum  
763 sequencing infrastructure globally, as the time until a variant that emerges in a low-  
764 sequencing rate environment is exported to a high-sequencing rate environment would  
765 increase. We explicitly investigated the potential effects of misspecification of the mobility  
766 matrix on our results by multiplying and dividing the mobility rate matrix by three,  
767 representing substantially increased and reduce spread, respectively (Extended Data Fig.  
768 10b). A reduced rate would further increase the gains to be effected by the establishment of  
769 sequencing infrastructure globally. Even if the mobility rate was increased three-fold, the  
770 strategies with increased solidarity in the global distribution of genomic surveillance  
771 infrastructure yield strongly improved performance compared to the 2022 baseline. Hence,  
772 our results are robust to specifics of the mobility dynamics.

773  
774 Our analyses wholly rely on GISAID data to inform the global landscape of respiratory virus  
775 genomic surveillance infrastructure. In some countries, incomplete or absent deposition of  
776 sequence data in GISAID may result in sequencing rates computed from GISAID data being  
777 unreliable. For example, the zero-covid policy in China that was in place for parts of 2022,  
778 combined with a relatively small number of sequences in GISAID, suggest that submission  
779 rates to GISAID may not accurately represent China's true genomic surveillance capacity<sup>51</sup>.  
780 We tested the possible implications of such biases on our results by comparing the results if  
781 all epidemic simulations with new variant viruses originating in China were removed. When  
782 China was removed from the set of possible epidemic origin locations, the conclusions  
783 regarding the performance of the different strategies for the global distribution of genomic  
784 surveillance infrastructure remained unchanged. The representativeness of GISAID data is  
785 further supported by the extremely strong correlation between sequence output and GDP  
786 (Spearman's  $\rho = 0.79$ ,  $P = 6.3 \times 10^{-41}$ ).

#### 787 788 **Data availability**

789  
790 Data on global population sizes are available from the United Nations World Population  
791 Prospects 2022 (<https://population.un.org/wpp/Download/Standard/MostUsed/>). Data on  
792 country GDP (<https://data.worldbank.org/indicator/NY.GDP.PCAP.CD>) and income  
793 classification ([https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-  
794 bank-country-and-lending-groups](https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)) is available from the World Bank. The Global  
795 Transnational Mobility Dataset is available from the Global Mobilities Project  
796 (<https://migrationpolicycentre.eu/globalmobilities/dataset/>). Metadata on global SARS-CoV-2  
797 and seasonal influenza virus sequencing rates were extracted from GISAID  
798 ([www.gisaid.org](http://www.gisaid.org)). Raw global epidemic simulation output is available at  
799 <https://zenodo.org/records/10051237>.

#### 800 801 **Code availability**

802  
803 Custom code and data used to generate the results in this study is publicly available at  
804 [https://github.com/AMC-LAEB/genomic\\_surveillance\\_solidarity](https://github.com/AMC-LAEB/genomic_surveillance_solidarity).

805



## 807 References


808

- 809 1. Viana, R. *et al.* Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in  
810 southern Africa. *Nature* **603**, 679–686 (2022).
- 811 2. Ladner, J. T. & Sahl, J. W. Towards a post-pandemic future for global pathogen  
812 genome sequencing. *PLOS Biol.* **21**, e3002225 (2023).
- 813 3. Hill, V. *et al.* Toward a global virus genomic surveillance network. *Cell Host Microbe*  
814 **31**, 861–873 (2023).
- 815 4. World Health Organization (WHO). *International Health Regulations*. (2005).
- 816 5. Brito, A. F. *et al.* Global disparities in SARS-CoV-2 genomic surveillance. *Nat.*  
817 *Commun.* **13**, 7003 (2022).
- 818 6. Wu, F. *et al.* A new coronavirus associated with human respiratory disease in China.  
819 *Nature* **579**, 265–269 (2020).
- 820 7. Krammer, F. SARS-CoV-2 vaccines in development. *Nature* **586**, 516–527 (2020).
- 821 8. null, null. Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans.  
822 *N. Engl. J. Med.* **360**, 2605–2615 (2024).
- 823 9. Wohl, S., Lee, E. C., DiPrete, B. L. & Lessler, J. Sample size calculations for pathogen  
824 variant surveillance in the presence of biological and systematic biases. *Cell Reports*  
825 *Med.* **4**, (2023).
- 826 10. Hill, V., Ruis, C., Bajaj, S., Pybus, O. G. & Kraemer, M. U. G. Progress and  
827 challenges in virus genomic epidemiology. *Trends Parasitol.* **37**, 1038–1049 (2021).
- 828 11. Méder, Z. Z. & Somogyi, R. Optimal capacity sharing for global genomic surveillance.  
829 *Epidemics* **43**, 100690 (2023).
- 830 12. Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data - from  
831 vision to reality. *Euro surveillance : bulletin European sur les maladies transmissibles*  
832 *= European communicable disease bulletin* vol. 22 at [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494)  
833 [7917.ES.2017.22.13.30494](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494) (2017).
- 834 13. Balcan, D. *et al.* Seasonal transmission potential and activity peaks of the new  
835 influenza A(H1N1): a Monte Carlo likelihood analysis based on human mobility. *BMC*  
836 *Med.* **7**, 45 (2009).
- 837 14. Broeck, W. Van den *et al.* The GLEaMviz computational tool, a publicly available  
838 software to explore realistic epidemic spreading scenarios at the global scale. *BMC*  
839 *Infect. Dis.* **11**, 37 (2011).
- 840 15. Sangiovanni, Andrea; Viehoff, J. Solidarity in Social and Political Philosophy. in *The*  
841 *Stanford Encyclopedia of Philosophy (Summer 2023, Metaphysics Research Lab,*  
842 *Stanford University 2023)*.
- 843 16. Prainsack, Barbara; Buyx, A. Solidarity: Reflections on an Emerging Concept in  
844 Bioethics. *Nuff. Counc. Bioeth.* (2011).
- 845 17. Taylor, A. L. *et al.* Solidarity in the wake of COVID-19: reimagining the International  
846 Health Regulations. *Lancet* **396**, 82–83 (2020).
- 847 18. Toebe, B., Forman, L. & Bartolini, G. Toward Human Rights-Consistent Responses  
848 to Health Emergencies: What Is the Overlap between Core Right to Health  
849 Obligations and Core International Health Regulation Capacities? *Health Hum. Rights*  
850 **22**, 99–111 (2020).
- 851 19. Boyle, L. *et al.* Selective sweeps in SARS-CoV-2 variant competition. *Proc. Natl.*  
852 *Acad. Sci.* **119**, e2213879119 (2022).
- 853 20. Wilkinson, E. *et al.* A year of genomic surveillance reveals how the SARS-CoV-2  
854 pandemic unfolded in Africa. *Science (80- )*. **374**, 423–431 (2021).
- 855 21. Tegally, H. *et al.* The evolving SARS-CoV-2 epidemic in Africa: Insights from rapidly  
856 expanding genomic surveillance. *Science (80- )*. **378**, eabq5358 (2023).

- 857 22. Hill, V. *et al.* The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in  
858 the UK. *Virus Evol.* **8**, veac080 (2022).
- 859 23. Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage  
860 B.1.1.7 in England. *Science (80-. )*. **372**, eabg3055 (2021).
- 861 24. Anderson, A. S. A lightspeed approach to pandemic drug development. *Nat. Med.* **28**,  
862 1538 (2022).
- 863 25. Newland, M. *et al.* Improving pandemic preparedness through better, faster influenza  
864 vaccines. *Expert Rev. Vaccines* **20**, 235–242 (2021).
- 865 26. Han, A. X. *et al.* SARS-CoV-2 diagnostic testing rates determine the sensitivity of  
866 genomic surveillance programs. *Nat. Genet.* **55**, 26–33 (2023).
- 867 27. Salyer, S. J. *et al.* The first and second waves of the COVID-19 pandemic in Africa: a  
868 cross-sectional study. *Lancet* **397**, 1265–1275 (2021).
- 869 28. Kalia, K., Saberwal, G. & Sharma, G. The lag in SARS-CoV-2 genome submissions to  
870 GISAID. *Nat. Biotechnol.* **39**, 1058–1060 (2021).
- 871 29. Sahadeo, N. S. D. *et al.* Implementation of genomic surveillance of SARS-CoV-2 in  
872 the Caribbean: Lessons learned for sustainability in resource-limited settings. *PLOS*  
873 *Glob. Public Heal.* **3**, e0001455 (2023).
- 874 30. Lavery, J. V, Porter, R. M. & Addiss, D. G. Cascading failures in COVID-19 vaccine  
875 equity. *Science (80-. )*. **380**, 460–462 (2023).
- 876 31. Wouters, O. J. *et al.* Challenges in ensuring global access to COVID-19 vaccines:  
877 production, affordability, allocation, and deployment. *Lancet* **397**, 1023–1034 (2021).
- 878 32. Ortiz, J. R. & Neuzil, K. M. Influenza Immunization in Low- and Middle-Income  
879 Countries: Preparing for Next-Generation Influenza Vaccines. *J. Infect. Dis.* **219**, S97–  
880 S106 (2019).
- 881 33. Moodley, K. *et al.* Ethics and governance challenges related to genomic data sharing in  
882 southern Africa: the case of SARS-CoV-2. *Lancet Glob. Heal.* **10**, e1855–e1859  
883 (2022).
- 884 34. Ramsay, M. African genomic data sharing and the struggle for equitable benefit.  
885 *Patterns* **3**, 100412 (2022).
- 886 35. Preiser, W., Engelbrecht, S. & Maponga, T. No point in travel bans if countries with  
887 poor surveillance are ignored. *Lancet* **399**, 1224 (2022).
- 888 36. Carlson, C. *et al.* Save lives in the next pandemic: ensure vaccine equity now. *Nature*  
889 **626**, 952–953 (2024).
- 890 37. Lancet, T. The Pandemic Treaty: shameful and unjust. *Lancet* **403**, 781 (2024).
- 891 38. Olawoye, I. B. *et al.* Emergence and spread of two SARS-CoV-2 variants of interest in  
892 Nigeria. *Nat. Commun.* **14**, 811 (2023).
- 893 39. Mashe, T. *et al.* Genomic epidemiology and the role of international and regional  
894 travel in the SARS-CoV-2 epidemic in Zimbabwe: a retrospective study of routinely  
895 collected surveillance data. *Lancet Glob. Heal.* **9**, e1658–e1666 (2021).
- 896 40. Olono, A., Mitesser, V., Happi, A. & Happi, C. Building genomic capacity for  
897 precision health in Africa. *Nat. Med.* (2024) doi:10.1038/s41591-024-03081-9.
- 898 41. Onywera, H. *et al.* Boosting pathogen genomics and bioinformatics workforce in  
899 Africa. *Lancet Infect. Dis.* **24**, e106–e112 (2024).
- 900 42. Omotoso, O. E. *et al.* Bridging the genomic data gap in Africa: implications for global  
901 disease burdens. *Global. Health* **18**, 103 (2022).
- 902 43. West-Oram, P. G. N. & Buyx, A. Global Health Solidarity. *Public Health Ethics* **10**,  
903 212–224 (2017).
- 904 44. Prainsack, B. & Buyx, A. *Solidarity in Biomedicine and Beyond. Cambridge Bioethics*  
905 *and Law* (Cambridge University Press, 2017). doi:DOI: 10.1017/9781139696593.
- 906 45. James, Chris; Savedoff, W. Risk Pooling and Redistribution in Health Care: An



- 907            Analysis of Attitudes toward Solidarity. in *World Health Report (2010) Background*  
908            *paper No. 5* (2010).
- 909    46.    Genschel, Philipp; Hemerijck, A. Solidarity in Europe. in *01 EUI Policy Brief*. (2018).
- 910    47.    Baute, S. & de Ruijter, A. EU health solidarity in times of crisis: explaining public  
911            preferences towards EU risk pooling for medicines. *J. Eur. Public Policy* **29**, 1183–  
912            1205 (2022).
- 913    48.    Brockmann, D. & Helbing, D. The Hidden Geometry of Complex, Network-Driven  
914            Contagion Phenomena. *Science (80-. )*. **342**, 1337–1342 (2013).
- 915    49.    Deutschmann, E., Recchi, E. & Vespe, M. Assessing Transnational Human Mobility  
916            on a Global Scale BT - Migration Research in a Digitized World: Using Innovative  
917            Technology to Tackle Methodological Challenges. in (eds. Pötzschke, S. & Rinke, S.)  
918            169–192 (Springer International Publishing, 2022). doi:10.1007/978-3-031-01319-5\_9.
- 919    50.    Klamser, P. P. *et al.* Inferring country-specific import risk of diseases from the world  
920            air transportation network. *arXiv e-prints* arXiv:2304.12087 at  
921            <https://doi.org/10.48550/arXiv.2304.12087> (2023).
- 922    51.    Preiser, W. & Maponga, T. So far, no novel SARS-CoV-2 variants from  
923            Beijing&#x2014;and hopefully better scientific cooperation going forward. *Lancet*  
924            **401**, 621–622 (2023).
- 925




926  
927

928 **Extended Data Fig 1. The global distribution of sequencing output.**

929 **(A)** The cumulative proportion of the global population that accounts for a cumulative  
930 proportion of global sequence output for SARS-CoV-2. Data on sequencing output  
931 corresponds to SARS-CoV-2 sequences in GISAID with collection date in 2022. Solid grey  
932 lines show the smallest proportion of the population that accounts for 50% of sequencing  
933 output. Dashed grey lines show the smallest proportion of sequencing output that is  
934 accounted for by 50% of the global population. **(B)** The cumulative proportion of the global  
935 population that accounts for a cumulative proportion of global seasonal influenza sequence  
936 output. Data on sequencing output corresponds to seasonal influenza sequences collected  
937 from humans in GISAID with collection date in 2018. Solid grey lines show the smallest  
938 proportion of the population that accounts for 50% of sequencing output. Dashed grey lines  
939 show the smallest proportion of sequencing output that is accounted for by 50% of the global  
940 population.

941  
942  
943

944




945

946


**Extended Data Fig. 2. Validation of the metapopulation model against GLEAM.** For ten  
947 geographically representative countries, global variant spread was simulated, initialized in the  
948 country's capital city, in GLEAM. For each of the 10 index countries, all global countries'  
949 epidemic onset timings as simulated using GLEAM were compared against the countries'  
950 epidemic onset timings as simulated using the epidemic model used in this study. For both  
951 models, timings were computed as the median across 10 independent simulations.  
952 Simulations are for a variant  $R_e$  of 1.6.

953



954  
955  
956  
957  
958  
959  
960  
961


**Extended Data Fig. 3. Different scenarios of variant emergence.** For each of the values of variant  $R_e$ , the corresponding panel shows the epidemiological dynamics of variant and wildtype for that scenario of variant emergence, starting from the day of variant introduction. For each value of variant  $R_e$ , the scenario of variant emergence is characterized by a different value of wildtype  $R_e$  and wildtype prevalence at introduction.



962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974

**Extended Data Fig. 4. Validation of derived time to variant detection.** The red points show the relationship between time to detection simulated using binomial sampling (x-axis) and time to detection computed using the derived mathematical model (y-axis). The dashed grey line corresponds to  $y=x$ . Each panel corresponds to a different variant  $R_e$  and different scenario of variant emergence (i.e. a different value of wildtype  $R_e$  and wildtype prevalence at time of variant introduction). This illustrates that the equation is valid, unless the timescales of detection are smaller than the timescales at which the logistic growth dynamics do not hold (bottom left quadrant), e.g. when susceptible depletion occurs before the variant is expected to be detected (see Methods).

975



976

977

978

979

980

981

982

983


984

985

986

**Extended Data Fig. 5. The dependence of time to variant detection on sequencing rate for varying scenario of variant emergence. (A) Relationship between sequencing rate and the number of days until the variant will have been detected with 95% confidence. The small black tick marks on the  $x$ -axes in this plot and in **B** show country-specific SARS-CoV-2 sequencing rates for 2022. Each panel corresponds to a different scenario of variant emergence, characterized by a wildtype (wt)  $R_e$  and wildtype prevalence at introduction. In each panel, lines are colored by value of variant  $R_e$ . (B) Relationship between sequencing rate and the reduction in time to variant detection that results from increasing the existing sequencing rate ( $x$ -axis) by 1 S/M/wk.**






987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998

**Extended Data Fig. 6. The dependence of the number of variant infections by day of detection on sequencing rate for varying scenario of variant emergence. (A) Relationship between sequencing rate and the number of infections by the day the variant will have been detected with 95% confidence. The small black tick marks on the  $x$ -axes in this plot and in **B** show country-specific SARS-CoV-2 sequencing rates for 2022. Each panel corresponds to a different scenario of variant emergence, characterized by a wildtype (wt)  $R_e$  and wildtype prevalence at introduction. In each panel, lines are colored by value of variant  $R_e$ . (B) Relationship between sequencing rate and the reduction in the number of variant infections by the day of variant detection that results from increasing the existing sequencing rate ( $x$ -axis) by 1 S/M/wk.**

999



1000

1001

1002

1003

1004

1005


1006

1007

1008


1009

**Extended Data Fig. 7. Time to global variant detection by strategy and scenario of variant emergence. (A)** Time to global variant detection by strategy for the global distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype prevalence ( $N = 10,000$  for each)). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points correspond to means. **(B)** Number of global variant infections by the day of first detection by strategy for the global distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype prevalence).



1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022

**Extended Data Fig. 8. Time to ascertainment of substantial variant proportion by strategy and scenario of variant emergence.** (A) Time until the variant was found to account for a substantial proportion of circulating virus in at least one country, by strategy for the global distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype prevalence). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points correspond to means. (B) Number of global variant infections by the day the variant was found to account for a substantial proportion of circulating virus in at least one country, by strategy for the global distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype prevalence).



1023

1024 **Extended Data Fig. 9. The relationship between sequencing rate and error in estimated**  
1025 **variant proportion.** For each sequencing rate given on the *x*-axis, for varying true variant  
1026 proportion and population size, the *y*-axis shows the maximum error in the estimated weekly  
1027 proportion of total infections attributable to the variant. This maximum error is presented for  
1028 varying confidence (i.e. the *y*-axis represents the error that the error in the estimated variant  
1029 proportion relative to the true variant proportion will be smaller than *n*% of the time, for *n*  
1030 given by the confidence level).


1031

1032

1033

1034

1035



1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049

**Extended Data Fig. 10. Sensitivity analyses for time to detection.**

(A) Sensitivity analysis for time to GISAID submission. Time to global variant detection by strategy for the global distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype prevalence). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points correspond to means. Given a sequence in GISAID's computed turnaround time  $T$ , a sequence's adjusted turnaround time  $\tilde{T}$  was equal to  $\phi T$ . These adjusted turnaround times were used to inform country-specific sequencing infrastructure in the global genomic surveillance simulations. (B) Sensitivity analysis for mobility rate. Time to global variant detection by strategy for the global distribution of respiratory virus surveillance infrastructure, by variant  $R_e$ , for varying scenario of variant emergence (characterized by wildtype (wt)  $R_e$  and wildtype prevalence). Thin and thick lines correspond to 95% and 50% CIs, respectively. Points correspond to means. Each row corresponds to a modified global

1050 mobility rate (top: baseline mobility rate multiplied by 3; bottom: baseline mobility rate  
1051 divided by 3).  
1052